Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Humana (HUM) to $290 from $387 and keeps an Overweight rating on the shares. Following the bulk of earnings, the firm is updating models and detailed earnings bridges for each large cap MCO. Wells is not incorporating any election-related changes to its valuation framework at this time.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target lowered to $290 from $395 at Cantor Fitzgerald
- Humana price target raised to $253 from $250 at Barclays
- Humana’s Medicare Advantage Star Ratings Drop: Legal Battle Looms Over 2025 Projections and Potential Revenue Impact
- Humana Inc. Reports Mixed Q3 2024 Results
- HUM Earnings: Humana Reports Better-than-Expected Q3 Results, Updates Outlook